A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00741442
Recruitment Status : Completed
First Posted : August 26, 2008
Last Update Posted : February 6, 2014
Information provided by (Responsible Party):
Ardea Biosciences, Inc.

August 25, 2008
August 26, 2008
February 6, 2014
July 2008
April 2009   (Final data collection date for primary outcome measure)
To compare the proportion of subjects whose serum uric acid (sUA) level is <6.0 mg/dL following 4 weeks of continuous treatment with RDEA806. [ Time Frame: 4 weeks ]
Same as current
Complete list of historical versions of study NCT00741442 on Archive Site
  • To evaluate the proportion of subjects whose sUA levels are <6.0 mg/dL, <5.0 mg/dL and <4.0 mg/dL, at each visit. [ Time Frame: 4 weeks ]
  • To evaluate the absolute and percent reduction from baseline in sUA levels [ Time Frame: 4 weeks ]
  • To evaluate percent change in 24-hour urine uric acid level [ Time Frame: 4 weeks ]
Same as current
Not Provided
Not Provided
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
The purpose of this study is to determine whether RDEA806 is effective in the treatment of hyperuricemia in gout patients.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: RDEA806
    Uricosuric agent for the treatment of gout
  • Drug: Placebo
    Matching Placebo.
  • Experimental: 1
    RDEA806 400 mg qd
    Intervention: Drug: RDEA806
  • Experimental: 3
    RDEA806 400 mg bid
    Intervention: Drug: RDEA806
  • Placebo Comparator: 2
    Placebo QD
    Intervention: Drug: Placebo
  • Placebo Comparator: 4
    Placebo BID
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2009
April 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is hyperuricemic: screening serum uric acid ≥8 mg/dL.
  • Patient meets one or more of the 1977 ARA criteria for the diagnosis of gout.
  • Patient is willing and able to give informed consent and adhere to visit/protocol schedules
  • All female subjects of child-bearing potential must agree to use a barrier method of birth control (e.g. condom, diaphragm or cap).

Exclusion Criteria:

  • Consumes more than 14 drinks of alcohol per week.
  • History or suspicion of drug abuse.
  • History of kidney stones, rheumatoid arthritis or other autoimmune disease, significant cardiac dysfunction.
  • Diabetes Mellitus requiring treatment
  • Confirmed or suspected HIV-1 infection.
  • Malignancy, except treated non-melanomatous skin cancer and cervical dysplasia.
  • Uncontrolled hypertension.
  • Inadequate renal function.
  • Hemoglobin < 8 g/dL (males) or < 7 g/dL (females).
  • ALT, AST , or GGT 2 x ULN
  • Active peptic ulcer disease.
  • Requires long-term use of salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; IV colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole; trimethoprim.
  • Pregnant or breast feeding.
  • Use of an investigational drug within 4 weeks prior to study drug administration.
  • Known hypersensitivity or allergy to RDEA806 or colchicine or any components in their formulations.
  • Any other medical or psychological condition which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
  • History of cardiac abnormalities including abnormal and clinically relevant ECG changes.
  • Conditions predisposing to QT prolongation.
  • Any use of concomitant medications that prolong the QT/QTc interval within 14 days prior to Day 1.
  • Subjects with a QTcF interval >450 milliseconds at screening or on Day -1 or at pre-dose (Hour 0) on Day 1.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
Not Provided
Study Director: Vijay Hingorani, MD, PhD, MBA Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP